Vanda Pharmaceuticals Inc (NASDAQ:VNDA) shares, rose in value, with the stock price up by 3.12% to the previous day’s close as strong demand from buyers drove the stock to $4.62.
Actively observing the price movement in the last trading, the stock closed the session at $4.48. The PE ratio was 105.72 over 12-month period. Referring to stock’s 52-week performance, its high was $7.00, and the low was $3.30. On the whole, VNDA has fluctuated by 18.77% over the past month.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 194.5M, with a low estimate of 48.5M and a high estimate of 48.5M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 48.5M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that VNDA’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 2.93, with the price of VNDA currently trading nearly 2.24% and 8.13% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 53.57, while the 7-day volatility ratio is showing 4.42% which for the 30-day chart, stands at 7.42%. Furthermore, Vanda Pharmaceuticals Inc (VNDA)’s beta value is 0.74, and its average true range (ATR) is 0.32.
A comparison of Vanda Pharmaceuticals Inc (VNDA) with its peers suggests the former has fared considerably weaker in the market. VNDA showed an intraday change of 3.12% in last session, and over the past year, it shrunk by -26.55%%.
Data on historical trading for Vanda Pharmaceuticals Inc (NASDAQ:VNDA) indicates that the trading volumes over the past 3 months, they’ve averaged 2.34 million. According to company’s latest data on outstanding shares, there are 57.53 million shares outstanding.
Nearly 5.26% of Vanda Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 86.89% of the company’s shares. The stock has risen by 9.48% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VNDA stock heading into the next quarter.
